[go: up one dir, main page]

MX2012004522A - Tratamiento que usa celulas adultas maduras reprogramadas. - Google Patents

Tratamiento que usa celulas adultas maduras reprogramadas.

Info

Publication number
MX2012004522A
MX2012004522A MX2012004522A MX2012004522A MX2012004522A MX 2012004522 A MX2012004522 A MX 2012004522A MX 2012004522 A MX2012004522 A MX 2012004522A MX 2012004522 A MX2012004522 A MX 2012004522A MX 2012004522 A MX2012004522 A MX 2012004522A
Authority
MX
Mexico
Prior art keywords
cells
patient
retrodifferentiated
transdifferentiated
treatment
Prior art date
Application number
MX2012004522A
Other languages
English (en)
Inventor
Ilham Mohamed Saleh Saeed Abuljadayel
Original Assignee
Tristem Trading Cyprus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tristem Trading Cyprus Ltd filed Critical Tristem Trading Cyprus Ltd
Publication of MX2012004522A publication Critical patent/MX2012004522A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)

Abstract

Un método para tratar diversas enfermedades, trastornos o afecciones en pacientes usando células reprogramadas tales como células retrodiferenciadas, transdiferenciadas o rediferenciadas; el método comprende obtener células comprometidas de la paciente, retrodiferenciación de las células comprometidas para obtener células objetivo retrodiferenciadas y administrar las células retrodiferenciadas al paciente; en ciertas modalidades, el método comprende obtener células comprometidas del paciente, transdiferenciando las células comprometidas para obtener células objetivo transdiferenciadas y la administración de las células objetivo transdiferenciadas al paciente; las células objetivo retrodiferenciadas o transdiferenciadas reparan o reponen tejidos o células en el paciente.
MX2012004522A 2009-10-19 2009-10-19 Tratamiento que usa celulas adultas maduras reprogramadas. MX2012004522A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2009/051396 WO2011048350A1 (en) 2009-10-19 2009-10-19 Treatment using reprogrammed mature adult cells

Publications (1)

Publication Number Publication Date
MX2012004522A true MX2012004522A (es) 2012-05-08

Family

ID=42199514

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004522A MX2012004522A (es) 2009-10-19 2009-10-19 Tratamiento que usa celulas adultas maduras reprogramadas.

Country Status (17)

Country Link
EP (1) EP2490702A1 (es)
JP (1) JP6073135B2 (es)
KR (1) KR101766203B1 (es)
CN (1) CN102647989A (es)
AU (1) AU2009354350B2 (es)
CA (1) CA2781522A1 (es)
CH (1) CH704227B1 (es)
CU (1) CU24006B1 (es)
IL (1) IL218902A (es)
MA (1) MA33740B1 (es)
MX (1) MX2012004522A (es)
PH (1) PH12012500714A1 (es)
RU (1) RU2635317C2 (es)
TN (1) TN2012000157A1 (es)
UA (1) UA109265C2 (es)
WO (1) WO2011048350A1 (es)
ZA (1) ZA201202664B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044681A1 (en) * 2014-09-18 2016-03-24 North Carolina State University Mammalian lung spheroids and lung spheroid cells and uses thereof
JP6113133B2 (ja) 2014-11-06 2017-04-12 日本メナード化粧品株式会社 幹細胞の未分化状態維持剤及び増殖促進剤
CN108290939B (zh) 2015-10-16 2023-01-13 纽约市哥伦比亚大学理事会 用于抑制谱系特异性抗原的组合物和方法
CN107114355A (zh) * 2016-08-01 2017-09-01 北京世纪劲得生物技术有限公司 一种脂肪细胞保护液及其制备方法
KR102709603B1 (ko) * 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
CN109731012A (zh) * 2017-10-30 2019-05-10 邹兆中 提高生物免疫治疗有效物质活性的方法
CN109706119B (zh) * 2018-04-13 2020-11-27 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
KR20200025210A (ko) * 2018-08-29 2020-03-10 주식회사 스템모어 모유두 세포의 배양용 조성물 및 이를 이용한 모유두 세포의 배양 방법
WO2021240204A1 (en) * 2020-05-23 2021-12-02 Pakravan Nafiseh Sperm head for resolution of inflammation, tissue repair & regeneration, and restoration of tissue function: new approach of cell therapy
CN114231481B (zh) * 2021-12-21 2023-07-18 中国人民解放军总医院 一种重编程真皮成纤维细胞为内皮祖细胞的化学诱导方法
WO2023217125A1 (zh) * 2022-05-10 2023-11-16 上海赛立维生物科技有限公司 前列腺前体样细胞、细胞制剂及其制备方法和应用
WO2024050517A1 (en) * 2022-09-02 2024-03-07 The University Of North Carolina At Chapel Hill Methods of making and using anticancer reprogrammed b cells
WO2025143018A1 (ja) * 2023-12-28 2025-07-03 サントリーホールディングス株式会社 好奇心の低下抑制又は改善用組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US7112440B2 (en) * 1995-02-02 2006-09-26 Ghazi Jaswinder Dhoot Method of increasing the relative number of CD45 low cells in a cell population
US9068164B1 (en) * 1995-02-02 2015-06-30 Tristem Trading (Cyprus) Limited Method of preparing an undifferentiated cell
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
JPH10503053A (ja) * 1995-05-02 1998-03-17 フィリップス エレクトロニクス ネムローゼ フェンノートシャップ カラー陰極線管
US20050037490A1 (en) * 1999-10-29 2005-02-17 Lawrence Rosenberg Medium for preparing dedifferentiated cells
TWI288779B (en) * 2002-03-28 2007-10-21 Blasticon Biotech Forschung Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
US20080112937A1 (en) * 2004-07-22 2008-05-15 Lewis T Williams Method of Producing Autologous Embryonic Stem Cells
EP2414510A4 (en) * 2009-04-03 2013-04-17 Mclean Hospital Corp INDUCED PLURIPOTENTIAL STEM CELLS

Also Published As

Publication number Publication date
CH704227B1 (fr) 2015-05-15
UA109265C2 (uk) 2015-08-10
WO2011048350A1 (en) 2011-04-28
PH12012500714A1 (en) 2012-10-29
ZA201202664B (en) 2013-02-27
MA33740B1 (fr) 2012-11-01
AU2009354350A1 (en) 2012-04-19
RU2635317C2 (ru) 2017-11-10
CA2781522A1 (en) 2011-04-28
IL218902A0 (en) 2012-06-28
JP6073135B2 (ja) 2017-02-01
CN102647989A (zh) 2012-08-22
CU24006B1 (es) 2014-06-27
JP2013508343A (ja) 2013-03-07
EP2490702A1 (en) 2012-08-29
TN2012000157A1 (en) 2013-12-12
KR20120099686A (ko) 2012-09-11
KR101766203B1 (ko) 2017-08-08
CU20120063A7 (es) 2012-10-15
AU2009354350B2 (en) 2015-09-03
RU2012120713A (ru) 2013-11-27
IL218902A (en) 2017-06-29

Similar Documents

Publication Publication Date Title
TN2012000157A1 (en) Treatment using reprogrammed mature adult cells
Salgado et al. Tissue engineering and regenerative medicine: past, present, and future
MX2019005130A (es) Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente.
WO2012071526A3 (en) Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
MX2011009751A (es) Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
WO2007131232A3 (en) Compositions and their uses directed to ptpr alpha
MX2013002381A (es) Celulas precursoras cd27 1 derivadas de medula osea para reparacion cardiaca.
WO2011079261A3 (en) Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
EP2703481A4 (en) BROWN ADIPOCYTES OBTAINED FROM PLURIPOTENTIAL STEM CELLS, CELL AGGRAIN OBTAINED FROM PLURIPOTENTIAL STEM CELLS, METHOD OF MANUFACTURE THEREOF, AND CELL THERAPY AND MEDICAL THERAPY THEREFOR
CA2904533C (en) Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
NZ607195A (en) Methods for treating and/or reversing neurodegenerative diseases and/or disorders
WO2013078376A3 (en) Isoxazole treatments for diabetes
MX356814B (es) Métodos y composiciones para neuroprotección.
PH12014500739B1 (en) Methods for treating a stroke-related sensorimotor impairment using aminopyridines
MY157168A (en) Treatment using reprogrammed mature adult cells
WO2013033165A3 (en) Compositions, kits and methods for treating obesity, diabetes and hyperglycemia
WO2012177565A3 (en) Regulation of macrophage activation using mir - 125b
AR073910A1 (es) Tratamiento de diversas enfermedades, usando celulas adultas maduras reprogramadas.
UY32186A (es) Tratamiento que utiliza celulas adultas maduras reprogramadas
TR201204532T1 (tr) Yeniden programlanmış olgun yetişkin hücrelerinin kullanıldığı tedavi.
TH125509A (th) การรักษาที่ใช้เซลล์ของผู้ใหญ่ที่เจริญเต็มที่ที่ถูกโปรแกรมใหม่
WO2010110602A3 (ko) 인간 성체 줄기세포 또는 전구세포를 이용한 흑질 치밀부에서의 도파민 신경세포의 재생방법
RU2007100519A (ru) Способ лечения косоглазия у детей
UA49781U (uk) Спосіб лікування пилкової бронхіальної астми у дітей в період загострення
UA52233U (ru) Способ лечения грибковых кератитов